Division Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, The Netherlands.
Dutch National Health Care Institute (ZIN), Diemen, The Netherlands.
BMJ Open. 2023 Aug 28;13(8):e072309. doi: 10.1136/bmjopen-2023-072309.
Improving synergy among regulation, health technology assessment (HTA) and clinical guideline development is relevant as these independent processes are building on shared evidence-based grounds. The two objectives were first to assess how convergence of evidentiary needs among stakeholders may be achieved, and second, to determine to what extent convergence can be achieved.
Qualitative study using eight online dual-moderator focus groups.
Discussions had a European focus and were contextualised in four case studies on head and neck cancer, diabetes mellitus, multiple sclerosis and myelodysplastic syndromes.
Forty-two experienced (over 10 years) European regulators, HTA representatives and clinicians participated in the discussion.
Participants received information on the case study and research topic in advance. An introductory background presentation and interview guide for the moderators were used to steer the discussion.
Convergence may be achieved through improved communication institutionalised in multistakeholder early dialogues, shared definitions and shared methods. Required data sets should be inclusive rather than aligned. Deliberation and decision-making should remain independent. Alignment could be sought for pragmatic clinical trial designs and patient registries. Smaller and lower-income countries should be included in these efforts.
Actors in the field expressed that improving synergy among stakeholders always involves trade-offs. A balance needs to be found between the convergence of processes and the institutional remits or geographical independence. A similar tension exists between the involvement of more actors, for example, patients or additional countries, and the level of collaboration that may be achieved. Communication is key to establishing this balance.
监管、卫生技术评估(HTA)和临床指南制定之间的协同增效十分重要,因为这三个独立的过程都是基于共同的循证基础。这两个目标首先是评估如何实现利益相关者之间证据需求的趋同,其次是确定趋同的程度。
采用八项在线双主持人焦点小组的定性研究。
讨论以欧洲为重点,并在头颈部癌症、糖尿病、多发性硬化症和骨髓增生异常综合征四个案例研究中进行背景化。
42 名经验丰富(超过 10 年)的欧洲监管者、HTA 代表和临床医生参与了讨论。
参与者事先收到了案例研究和研究主题的信息。主持人使用了介绍性背景介绍和访谈指南来引导讨论。
通过在多利益攸关方早期对话中制度化的改进沟通、共享定义和共享方法,可以实现趋同。所需的数据集应该是包容性的,而不是一致性的。审议和决策应保持独立。可以为务实的临床试验设计和患者登记册寻求一致性。应包括较小和低收入国家。
该领域的参与者表示,提高利益相关者之间的协同增效总是需要权衡取舍。需要在流程趋同和机构职权范围或地理独立性之间找到平衡。更多的参与者(例如患者或其他国家)的参与程度和可能实现的协作水平之间也存在类似的紧张关系。沟通是建立这种平衡的关键。